US Plans to Restrict Potent Kratom Derivative
Summary
- Health Secretary Robert F. Kennedy Jr. announced a plan to restrict access to a potent kratom derivative.
- The compound, 7-hydroxymitragynine (7-OH), is amplified from kratom and binds to opioid receptors.
- Concerns exist about its addictive potential.
- The FDA will begin the process to classify 7-OH, with the DEA handling final steps.
Overall Sentiment: ⚪ Neutral
AI Explanation
Health Secretary Robert F. Kennedy Jr. has announced a plan to restrict access to a potent derivative of the kratom plant, known as 7-hydroxymitragynine (7-OH). This compound, which is amplified from kratom and readily available online and in vape stores, is used by millions for pain relief. Concerns have been raised about its addictive potential because it interacts with the brain's opioid receptors. The Food and Drug Administration (FDA) plans to officially "schedule" 7-OH, classifying its risks and benefits, with the Drug Enforcement Administration (DEA) handling the final regulatory steps.
Related Explanations
China's Economy Grows Amid Tariffs, US Policy Shifts Noted
0
13
Trump's Ukraine Policy Shift: Ambitions Meet Unclear Details
0
14
Spain Arrests Far-Right Leader Amidst Anti-Immigrant Riots
0
12
Europe Threatens Iran with UN Sanctions Over Nuclear Program
0
18
Canada Tightens Steel Imports Amid Global Trade Shifts
0
16
No comments yet. Be the first to start the discussion!